Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bordey will be primarily responsible for leading Cassava’s research and development efforts. Her scientific expertise will guide the Company’s preclinical program to evaluate simufilam as a potential treatment for TSC-related epilepsy, and potentially for additional pipeline indications. Dr. Bordey cu
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- Cassava Announces Agreement to Settle Securities Class Action LitigationGlobeNewswire
- Cassava Sciences rises 10% after market close on CEO stock buy [Seeking Alpha]Seeking Alpha
- Cassava Reports Q3 2025 Financials Results and Provides Business UpdateGlobeNewswire
- Cassava Sciences (NASDAQ:SAVA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SAVA
Earnings
- 3/3/25 - Beat
SAVA
Sec Filings
- 12/23/25 - Form 8-K
- 12/22/25 - Form 8-K/A
- 12/18/25 - Form 8-K
- SAVA's page on the SEC website